Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axonics Modulation Technologies Inc.

www.axonicsmodulation.com

Latest From Axonics Modulation Technologies Inc.

Axonics Appoints Chief Medical Officer

Former chief medical officer at the University of California, Karen Noblett, has been named as the CMO of neuromodulation technology company Axonics.

Appointments Medical Device

Hindsight 20/20: Raymond Cohen

Hindsight 20/20 is a new Q&A feature where medtech industry veterans share their long experience taking diverse businesses – be they start-ups or publicly-listed entities – from strength to strength and navigating through times of crises. This first instalment shines the spotlight on Raymond Cohen, who is currently CEO of venture-backed sacral neuromodulation company Axonics Modulation Technologies, Inc. The advice he gives includes not rushing into clinical studies too soon, try to go big with the fundraising and be very cautious when tackling a complex market like the US, among other things.

Business Strategies Hindsight 20/20

VC Deals Analysis: July Puts 2017 In A Good Place

The bull run in medtech venture financing activity continued in July, with deal volume going up once again from the previous month. Deal value was also solid, boosted by a number of sizeable rounds that helped lift the total amount of venture dollars raised this year to date to $3.88bn. Barring the possibility of a sudden drought in the VC financing landscape in the next few months, 2017 should be in a good position to beat 2016 in total deal value.

Financing StartUps and SMEs

INS 2017: Positive Initial Data Put Axonics On Next Big Wave Of Sacral Neuromodulation Growth

Axonics Modulation Technologies may be running against medtech giant Medtronic in the field of sacral neuromodulation for overactive bladder, but the smaller player is unfazed. Encouraging preliminary findings from its clinical study, revealed this week at the INS 2017 neuromodulation conference, is giving Axonics' technology the validation it needs. CEO Raymond Cohen is confident that the special features offered by the r-SNM system will galvanize what is already a fast-growing market.

Gynecology & Urology Clinical Trials
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Gynecological, Urological
  • Neurology, Nervous System
  • Alias(es)
  • American Restorative Medicine Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Axonics Modulation Technologies Inc.
  • Senior Management
  • Raymond W Cohen, CEO
    Dan L Dearen, COO & CFO
    Jiang Guangqiang, PhD, CTO
    Emilie Finiels, Senior Dir., Bus. Dev.
    John Woock, PhD, VP, Global Mktg. & Clinical Operations
    Karen L Noblett, MD, CMO
  • Contact Info
  • Axonics Modulation Technologies Inc.
    Phone: (949) 396-6322
    7575 Irvine Center Dr.
    Ste. 200
    Irvine, CA 92618
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register